Next Article in Journal
Atypical BRAF and NRAS Mutations in Mucosal Melanoma
Next Article in Special Issue
Comparative Cytogenetic Abnormalities in Paired Choroidal Melanoma Samples Obtained Before and After Proton Beam Irradiation by Transscleral Fine-Needle Aspiration Biopsy and Endoresection
Previous Article in Journal
Isoliquiritigenin Suppresses E2-Induced Uterine Leiomyoma Growth through the Modulation of Cell Death Program and the Repression of ECM Accumulation
Previous Article in Special Issue
Do GNAQ and GNA11 Differentially Affect Inflammation and HLA Expression in Uveal Melanoma?
Open AccessReview

HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target

1
Department of Ophthalmology, Leiden University Medical Center (LUMC), Albinusdreef 2, 2333 ZA Leiden, The Netherlands
2
Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center (LUMC), 2333 ZA Leiden, The Netherlands
3
Department of Cell and Chemical Biology, Leiden University Medical Center (LUMC), 2333 ZA Leiden, The Netherlands
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(8), 1132; https://doi.org/10.3390/cancers11081132
Received: 18 June 2019 / Revised: 17 July 2019 / Accepted: 1 August 2019 / Published: 7 August 2019
(This article belongs to the Special Issue Uveal Melanoma)
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, and gives rise to metastases in 50% of cases. The presence of an inflammatory phenotype is a well-known risk factor for the development of metastases. This inflammatory phenotype is characterized by the presence of high numbers of lymphocytes and macrophages, and a high expression of the HLA Class I and II antigens. An abnormal expression of HLA Class I may influence cytotoxic T lymphocyte (CTL) as well as Natural Killer (NK) cell responses. We provide a comprehensive review regarding the inflammatory phenotype in UM and the expression of locus- and allele-specific HLA Class I and of Class II antigens in primary UM and its metastases. Furthermore, we describe the known regulators and the role of genetics (especially chromosome 3 and BRCA-Associated Protein 1 (BAP1 status)), and, last but not least, the effect of putative therapeutic treatments on HLA expression. View Full-Text
Keywords: uveal melanoma; inflammation; HLA Class I; HLA Class II; chromosome 3; BAP1 uveal melanoma; inflammation; HLA Class I; HLA Class II; chromosome 3; BAP1
Show Figures

Graphical abstract

MDPI and ACS Style

Souri, Z.; Wierenga, A.P.; Mulder, A.; Jochemsen, A.G.; Jager, M.J. HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target. Cancers 2019, 11, 1132.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop